key: cord-0009472-fcacpc2e
authors: Nicholson, K.G.
title: ANTIVIRAL THERAPY: Respiratory Infections, Genital Herpes, and Herpetic Keratitis
date: 1984-09-15
journal: Lancet
DOI: 10.1016/s0140-6736(84)90604-4
sha: 2405ef9633b330bba233f68fa4e6812d155f714f
doc_id: 9472
cord_uid: fcacpc2e

nan

Therapeutics, Groby Road Hospital, Leicester THIS and remaining two articles of the series concentrate on the clinical application of antiviral agents in man.

Guidelines for treatment will be offered at the end of each section. VIRAL 

As a group, viral upper-respiratory-tract infections remain a leading cause of acute morbidity and economic loss throughout the world. Coryza and related symptoms are caused by a multitude of viruses and serotypes, some ofwhich are antigenically unstable and most of which are uncontrollable by vaccination. The common cold and influenza have long been major targets for antiviral chemotherapy. This section summarises data concerning influenza A and B, rhino, corona, and respiratory syncytial virus (RSV) infections against which antivirals have distinct but limited efficacy.

Both amantadine and the structurally related compound rimantadine are effective in 'the prevention of illness caused by H 1 Nl, H2N2, and H3N3 subtypes of influenza A(but not influenza B), both naturally acquired and experimentally induced, in man. Prophylactic efficacy has been reported in chronically sick and elderly people (including those in hospitalu2) and in children, as well as in healthy adults.4,5

On the evidence of controlled studies in many thousands of people, amantadine and rimantadine are about 50% effective in the prevention of infection but 70-10007o effective in the prevention or amelioration of illness : this distinction may be a desirable feature of prophylaxis since subclinical infection could confer immunity against reinfection.

Concern over side-effects has cast doubt on the usefulness of both amantadine and rimantadine. During an outbreak of influenza A with an attack-rate of 5 -20%, prevention or amelioration of -illness with amantadine is accomplished at the expense of minor central-nervous-system side-effects in about the same numbers. Rimantadine is far better tolerated in this respect ;4,6 even so, treatment with either drug is best restricted to people at high risk of infection or its consequences. When there is influenza A in the locality, possible candidates would be unvaccinated children and adults at high risk because of underlying disease, unvaccinated adults in essential community positions, household contacts of an index case, people unable to receive influenza vaccine because of egg sensitivity, and people living in semi-closed institutions.

In the USSR, intranasal administration of low-titre interferon-alpha was reported in 1969 to prevent influenza A,' but the results have yet to be substantiated. Oral inosiplex (isoprinosine, a 1:3 molar complex of inosine with dimethylaminoisopropanol-p-acetamidobenzoate), an immunopotentiator, and oral ribavirin have been evaluated in man; both had side-effects and yielded inconsistent results.

Oral treatment with amantadine or rimantadine, when started within the first 48 hours of symptoms, cuts the duration of fever and other effects of influenza A by 1-2 days-ie, it shortens illness by roughly one-third .4,1,1,1 The reduction of influenzal symptoms far outweighs the toxic effects. 8, 9 In addition, both agents may reduce the duration and amount of viral shedding, and oral amantadine accelerates resolution of the peripheral airways abnormalities that accompany influenza." To date there have been no controlled studies on the therapeutic effect of amantadine on primary influenza pneumonia; the few people who have been treated with 400-550 mg a day do not seem to have benefited.

Amantadine is not widely prescribed, and the reasons include unfamiliarity with the drug's antiviral effect, delayed medical consultation, and concern that patients with respiratory infections other than influenza A might be treated and placed at unnecessary risk from its toxic effects. During a known influenza outbreak, however, almost all individuals with acute onset of feverishness, cough, headache, myalgia, or anorexia, but without vomiting or diarrhoea, will have influenza and ought to be considered for treatment. More than 48 hours after the onset of symptoms, the prospect of benefit diminishes.

Amantadine, rimantadine, and ribavirin have been given by aerosol in the hope of providing high concentrations of drug throughout the airways with a minimum of toxicity. When compared with placebo, an amantadine aerosol of 1 gldl given for 20 minutes three times a day for 4 days accelerated recovery from naturally acquired influenza A virus infection. I It does, however, cause mild local side-effects, is inconvenient to administer, and seems no more effective than orally administered drug. Similar results were obtained with rimantadine aerosol in experimental influenza A infection. 12

Ribavirin has a broader spectrum of antiviral activity (including influenza B and RSV) than either amantadine or rimantadine but the results of oral treatment are inconsistent. When given by aerosol within the first 24 h of symptoms from H1N1 influenza (about 1 -15 g of drug in 23 h over 3 days) ribavirin accelerated the resolution of fever and illness and reduced virus shedding,13 but the improvements were at best modest and certainly insufficient to justify treatment in otherwise healthy subjects.

In influenza B ribavirin small-particle aerosol yields results similar to those in influenza A. To date, benefit has been seen only in patients with symptoms of less than 24 hours' duration who received 39 h of treatment in a total of 60 h.14 Respiratory Syncytial Virus: Treatment The therapeutic efficacy of ribavirin by aerosol has been further evaluated in adults infected with RSV experimentally and infants infected naturally. In the adult volunteers, ribavirin or placebo was started 2 days after intranasal inoculation with RSV and given for a total of 12 h each day for 3 days.l5 Ribavirin had no effect on minor upperrespiratory-tract symptoms (rhinitis, sore throat, sneezing, and lymphadenopathy), but did reduce systemic complaints, cough, and fever. The drug was then evaluated in a doubleblind controlled trial in children aged 1 week to 2 years who were in hospital with RSV pneumonia.16 Treatment was initiated a mean of 41/2 days after onset of symptoms; drug or placebo was administered almost continuously over 3-6 days into an infant oxygen hood, oxygen tent, or inhalation tubing of a respirator at an estimated dosage of 0 -82 mg/kg bodyweight per hour. By the end of treatment, infants receiving ribavirin had significantly greater improvement of cough, rales, intercostal muscle retraction, lethargy, arterial oxygen saturation, and viral shedding, whereas temperature, nasal congestion, rhinorrhoea, and wheezing were unaffected. In another study, daily 12-hour treatments over 5 days were associated with a more rapid resolution of bronchiolitis, and there was a trend towards a more rapid improvement of rhinitis with nasal discharge and obstruction." In no study were toxicity or side-effects noted. Ribavirin remains investigational, but there is a good case for its use in certain infants with RSV infection during the first few months of life-for example, those admitted to hospital and those with congenital heart disease or severe combined immunodeficiency disease.

Rhinovirus: Prophylaxis In 1973, Merigan et all8 showed that 1 -4x 10U of partly purified interferon-alpha given as frequent nasal sprays over 4 days could reduce the symptoms and virus shedding resulting from experimental infection with rhinovirus type 4 on the second day. Several groups have confirmed its efficacy in preventing or ameliorating illness, but its influence on the infection rate has varied. Since subclinical infection could confer immunity against reinfection a high infection rate is by no means disappointing. The main drawback is that, in the quantities necessary for a beneficial effect, intranasal interferon may cause local complications, and long-term use is inappropriate for prophylaxis of such a minor illness. Instead, it could be given for short periods to close contacts of an index case; indeed, preliminary data indicate that this approach may be both safe and effective. '9 The prophylactic effect of interferon-beta has been little studied to date. In one experiment 0 -25 ml of 10-10 U/ml was given into each nostril 3 times daily for 4 days, with rhinovirus challenge on the second day, but there was no reduction of symptoms or viral shedding.20 The scarcity of interferon in the past prompted several clinical trials of interferon inducers. Trials with topically applied polyinosinic/polycytidilic acid, a synthetic double-stranded RNA, pointed to some reduction in symptoms in volunteers infected with rhinovirus,21 but this agent is probably too toxic for use in such acute self-limited conditions. An investigational agent, a propanediamine called CP-20,961, seems non-toxic and consistently reduced symptoms of rhinovirus infection when administered as a nasal spray three or four times daily from day 1 before virus challenge. However, in a double-blind placebocontrolled study it was ineffective in the prevention of "colds" when given once daily for 30 days.22 The alternative approach of using specific antivirals has not so far yielded encouraging results. Enviroxime, a potent inhibitor of rhinovirus replication in vitro, has been evaluated clinically both in the United States and Britain. Although prophylactic administration of the drug has been associated with a reduction of certain symptoms, clinical scores of treatment and placebo groups have not differed significantly nor has the drug prevented infection.

Various compounds, including a propanediamine interferoninducer for the treatment of infection due to rhinovirus and vitamin C for the common cold, have so far yielded disappointing results.

There is anecdotal evidence that ribavirin by aerosol is useful in life-threatening parainfluenzavirus infection.

Gelfand et at23 treated a 6-month-old infant who had severe combined immunodeficiency and respiratory distress associated with isolation of parainfluenzavirus type 3. At the end of the first 5-day course he was afebrile, the respiratory 

The prophylactic effect of interferon-alpha has been investigated in volunteers experimentally infected with a strain of coronavirus 229 E.24 4x 106U was administered as an intranasal spray three times daily with coronavirus challenge on the second day of treatment. Compared with placebo, interferon-alpha significantly reduced the number of "colds" and virus shedding was also diminished. As in the studies with rhinovirus, subclinical infections were common in interferon recipients, thus allowing some subjects to acquire natural immunity.

Guidelines are summarised in table I.

Genital infection with herpes simplex virus, most commonly HSV type 2, is a major cause of genital ulceration worldwide. In Britain, the number of genital herpes simplex infections has increased by up to 23% per annum in recent years and in 1982 14 836 cases were reported from sexuallytransmitted-disease clinics. In the United States the numbers may be as high as 300 000 primary cases and 9 million recurrences each year. Primary lesions may persist for several weeks and are very painful. Some complications, such as urinary retention and central-nervous-system manifestations, require admission to hospital. Recurrences tend to be of shorter duration and less severe, though they still cause considerable morbidity; they are also associated with neonatal infection and represent a hazard to new sexual contacts.

Topical, oral, and intravenous preparations of acyclovir (ACV) all have a beneficial effect on virus shedding and healing, and generally improve pain and other symptoms. Topical ACV.-Treatment with 5o ACV cream in a propylene glycol base (applied 5 times daily for up to 10 days) has been evaluated in patients with first episodes of genital, herpes of less than 5 days' duration.25 It reduced the median duration of pain by 1 day, the time to complete healing by 5 days, and virus shedding by 6 days; in women the duration of dysuria was shortened by 5 days. In multicentre trials 5% ACV ointment in a polyethylene glycol base has been compared with placebo, the treatment starting within 6 days of onset of lesions and being applied 4 or 6 times daily for 7 days.26,27 In patients treated with ACV, the mean duration of viral shedding was reduced by about 3 days; the duration of pain and time to complete healing were also shortened by several days, but here the differences between ACV and placebo groups were not consistently significant. Topical ACV ointment had no effect on systemic sequelae (fever, headache, photophobia, neck stiffness) or dysuria and vaginal discharge.27

Om/4 CF.—Treatment with oral ACV (200 mg five times daily for 5 or 10 days) has similarly been investigated in patients with initial episodes of genital herpes of less than 5 or 6 days' duration.. Among ACV recipients, the mean duration of viral shedding was reduced by 7-14 days; pain was generally reduced, complete healing was accelerated, and the mean duration of dysuria and tender adenopathy was lessened by 1.3 3 and 2' 3 days respectively.

Intravenous ACV.-Intravenous ACV (5 mg/kg bodyweight 8-hourly for 5 days) has also been evaluated in patients with first attacks of genital herpes of less than 6 or 7 days' duration.31,32 It reduced the median duration of viral shedding by 4-11 days but had no consistent effect on duration of pain; time to complete healing, vaginal discharge, dysuria, sore throat, and other systemic complaints were all significantly reduced by the drug. Since intravenous and oral ACV have about the same efficacy, intravenous therapy can be reserved for hospital patients. Unfortunately, ACV treatment of primary genital herpes does not affect the recurrence rate.

Both topical and oral preparations of ACV have been evaluated in recurrent genital herpes.

Topical ACV.-Topical ACV ointment given four or six times daily for 5 days, but with treatment initiated within 48 h of onset of symptoms, shortens viral shedding at most by 1 day; pain is little affected, if at all; and there is essentially no beneficial effect on healing.26,27,33 Treatment with ACV cream (applied 5 times daily for 5 days) has been investigated in patients with recurrences of less than 24 hours' duration. It reduced the median duration of pain by 1' 5 days and of combined symptoms by 2 days.25

Oral ACV.-Oral ACV, 200 mg five times daily for 5 days, has similarly been evaluated in patients with recurrent episodes of less than 48 hours' duration;29,34,35 in one of the studies,35 patients began their own treatment a mean of 5 h after the first signs of symptoms of recurrence. Among the ACV recipients, the mean duration of viral shedding was reduced by 1-2 days; the duration of pain was unaffected even in the patient-initiated-therapy group; and the time to complete healing was reduced by 1 1-2 days.

Long-term prophylaxis with ACV has been under investigation as a means of preventing frequent debilitating recurrences. Straus et a136 conducted a trial of oral ACV (200 mg 5 times daily for 5 days then 3 times daily) or placebo in 35 patients (32 evaluable) who took the preparations for 125 days. The drug was well tolerated and there were significantly fewer recurrences in ACV recipients than placebo recipients (incidence of virologically confirmed recurrences 94% versus 12%). Douglas et a137 recorded the same incidence over 120 days in placebo recipients, compared with 29% in patients receiving 200 mg 5 times a day and 35% in those receiving 200 mg twice a day. In a British tria138 200 mg 4 times a day for 12 weeks reduced the recurrence rate to 14% (96% in placebo recipients). Straus et al isolated some drugresistant viruses from patients receiving ACV; but recurrences in these patients were associated with drugsensitive viruses. The place of prophylaxis with ACV remains uncertain, especially in view of the scarcity of data on long-term safety and development of resistance. Nevertheless, this agent does seem highly beneficial in patients with frequent recurrences and could be of enormous value in preventing the spread of infection. At present it should be reserved for the severest of cases. 

Besides ACV numerous therapies have been evaluated over the years but have mostly proven ineffective or been inadequately assessed. Initial studies with topical surfactants (such as ether and nonoxynol 9) and photodynamic inactivation with proflavine or neutral red suggested an antiviral effect, but placebo controlled studies showed none to be clinically active. Of the controlled investigations of topically applied idoxuridine (IDU), one showed that 0 -5% ointment was ineffective; 39 another suggested that 5% or 20% IDU in dimethylsulphoxide (DMSO) shortened viral shedding and aided healing,4 and another showed no clinical benefit from 30% IDU in DMSO for either primary or recurrent episodes.41

Topically administered 307o vidarabine cream seems equally ineffective.

Treatment with oral ribavirin (800 mg daily for 10 days) reportedly reduces the severity of pain and new lesion formation, but the results await confirmation. 2 Similarly, topical 2-deoxy-Dglucose, an inhibitor of envelope protein glycosylation, is said to accelerate recovery from initial infections and reduce the frequency and severity of recurrent episodes of genital herpes,4 though this agent has no therapeutic efficacy in animal models of infection.

Guidelines are summarised in table II. HERPETIC KERATITIS Ocular HSV infection, caused usually by HSV-1, is the leading communicable cause of blindness in developed countries. Primary ocular infection is acquired in early life and causes vesicles on the lids and a follicular blepharoconjunctivitis; in many instances the initial infection is subclinical. During recurrences viral replication initially produces small vesicular lesions in the corneal epithelial cells which may rupture and coalesce to form a dendritic or amoeboid ulcer, resulting in disability and pain. The condition may eventually progress to a deep stromal keratitis, necrosis, vascularisation, and scarring. Recurrent ocular herpes tends to be more severe than the primary infection: it arises in 26% of patients within 2 years of the initial episode and in 4307o within 2 years of a second attack. 44 Fortunately, there are several drugs with established efficacy in the treatment of ocular herpes.

Topically applied IDU has been in use since 1962 for the treatment of herpetic keratitis, the average cure rate being 76%.45 The cure rates for primary and recurrent cases are identical, and favourable results are commonly achieved during the first 7 days of therapy.46 Toxic side-effects are not infrequent, however, and the poor ocular penetration makes it less satisfactory for deep infections. IDU is no longer the drug of first choice.

Vidarabine, another poorly soluble compound, became the second antiviral to be widely used in the treatment of ocular herpes. On the evidence of numerous studies it is more effective than IDU in herpetic keratitis. In one double-blind trial comparing the two, treatment failure was recorded in 18-8% of IDU-treated patients but in only 9-5% of vidarabine-treated patients; the mean time to healing was about 7 days with either drug.47 Vidarabine coupled with corticosteroid therapy also seems beneficial in stromal disease48 despite its poor solubility and non-penetration into the healthy human eye.49 Toxic reactions, similar to those caused by IDU, develop in about 10% of patients. Despite its efficacy, many clinicians now favour acyclovir for initial management of ocular herpes.

Trifluorothymidine (F3TdR) has been in clinical use for more than a decade and is marketed in some European countries (not in the UK). In the USA it was approved in 1980 for the treatment of ocular herpes. Topically applied F3TdR has proved consistently more effective than IDU, with an average cure rate of 97% for dendritic and geographic corneal lesions.° The healing time has also been consistently shorter, by several days, for F3TdR than for IDU.51 It is also better than vidarabine for the treatment of amoeboid ulcers 52-54 but not dendritic or geographic ulcers, though the trend is towards superiority of F3TdR. F3TdR is effective also in the treatment of keratitis unresponsive to IDU or vidarabine, and is preferable to either agent for large ulcers and complicated disease. Adverse reactions to F3TdR are similar to those to IDU but seem less common. Since there are no reports of cross-toxicity between F3TdR and other ocular antivirals the drug can be used after reactions to other agents. Since there is no cross-resistance between these antivirals, an alternative agent can be confidently substituted if there is no clinical improvement within 7 days. In these circumstances, however, other possible causes for delayed healing should be excluded-for example, insufficient drug application, or an underlying stromal reaction.

Topical ACV has been thoroughly evaluated in clinical trials45,55-58 and has shown itself at least as effective as IDU, vidarabine, and F3TdR in the treatment of herpes keratitis, and possibly superior. 97% of patients with dendritic and geographic corneal lesions were healed by ACV. The rate of healing in ACV recipients seems distinctly faster than that with other antivirals-average healing time about 4 days.

Uncontrolled trials with an 0.1 % ophthalmic preparation ofbromovinyldeoxyuridine have yielded promising results in herpes simplex keratitis. Maugdal et al59tried this agent in 37 patients many of whom had been unresponsive to IDU or vidarabine. All patients responded favourably, with an average healing time of 7 -8 days for dendritic ulcers and 10 8 days for geographic lesions. No signs of toxicity or hypersensitivity were noted in any patient.

Topical application of interferon-alpha has been extensively investigated in dendritic keratitis, mostly with disappointing results. Exogenous interferon alone is not sufficiently effective; it must be used in conjunction with either debridement or another antiviral. 60 Sundmacher et al61 report that coadministration of F3TdR and interferon (3 x 107 U/ml) gave significantly faster healing than F3TdR alone, so there is scope for improvement in the treatment of HSV keratitis.

Guidelines are summarised in table III.

The suppression of A2 influenza in children by the chemoprophylactic use of amantadine

Prevention of nosocomial influenza infection with amantadine

Influenza A prophylaxis with amantadine in a boarding school

Study of rimantadine in the U.S S R a review of the literature

Antiviral activity of amantadine; a review of laboratory and clínical data

A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection

The results of controlled observations on the prophylaxis of influenza with interferon

Therapeutic efficacy of amantadine HCl and rimantadine HCI in naturally occurring influenza A2 respiratory illness in man

Successful treatment of naturally occurring influenza A/USSR/77 H1N1

Airway hyperreactivity and peripheral airway dysfunction in influenza A infection

Therapeutic effects of aerosolized amantadine in naturally acquired infection due to influenza A virus

Comparative therapeutic effect of aerosolized and oral rimantadine HCl in experimental human influenza A virus infection

Ribavirin small-particle aerosol treatment of influenza

Ribavirin aerosol treatment ofinfluenza B virus infection

Ribavirin treatment of experimental respiratory syncytial viral infection

Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection

Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants

Inhibition of respiratory virus infection by locally applied interferon

Intranasal interferon for contact prophylaxis against common cold in families

Failure of human fibroblast interferon to protect against rhinovirus infection

Evaluation of an interferon inducer in viral respiratory disease

Interferon inducers: propanediamines and related molecules

Ribavirin treatment of viral pneumonitis in severe combined immunodeficiency disease

Intranasal interferon as protection against experimental coronavirus infection in volunteers

Topical acyclovir in the treatment of genital herpes. a comparison with systemic therapy

A trial of topical acyclovir in genital herpes simplex virus infections

Double-blind controlled trial of topical acyclovir in genital herpes simplex virus infections

Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir

Oral acyclovir in the treatment of genital herpes

Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes

Intravenous acyclovir treatment for primary genital herpes

Intravenous acyclovir for the treatment of primary genital herpes

Topically administered acyclovir in the treatment of recurrent herpes simplex genitalis: a controlled trial

Controlled trial of oral acyclovir in the therapy of recurrent herpes simplex genitalis

Treatment of recurrent genital herpes simplex infections with oral acyclovir

Suppression of frequently recurring genital herpes a placebo-controlled double-blind trial of oral acyclovir

A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection

Prophylactic oral acyclovir in recurrent genital herpes

Comparison of the treatment of herpes genitalis in men with proflavine photoinactivation, idoxuridine ointment, and normal saline

A double-blind trial of idoxuridine in recurrent genital herpes

Ineffectiveness of topical idoxuridine in dimethylsulphoxide for therapy for genital herpes

Clinical efficacy of ribavirin in the treatment of genital herpes simplex virus infection

Successful treatment of human genital herpes infections with 2-deoxy-D-glucose

The recurrence of herpetic keratitis following idoxuridine therapy

Randomised double-blind trial of acyclovir and idoxuridine in dendritic corneal ulceration

The epidemiology and chemotherapy of herpes simplex keratitis and herpes simplex skin infections

Vidarabine therapy of simple and IDU-complicated herpetic keratitis

Adenine arabinoside in herpes simplex karatitis, treatment of idoxuridinefailure epithelial disease, and combined corticosteroid therapy in stromal keratitis

Intraocular penetration of adenine arabinoside and idoxuridine—therapeutic implications in clinical herpetic uveitis

Clinical evaluation of trifluorothymidine in the treatment of herpes simplex corneal ulcers

Clinical evaluation of adenine arabinoside and trifluorothymidine m the treatment of corneal ulcers caused by herpes simplex virus

Treatment of amoeboid herpetic ulcers with adenine arabinoside or trifluorothymidine

A coded clinical evaluation of adenine arabinoside and trifluorothymidine in the treatment of ulcerative herpetic keratitis

A comparison of acyclovir and idoxuridine as treatment for ulcerative herpetic keratitis

Comparative trial of acyclovir and adenine arabinoside in the treatment of herpes simplex corneal ulcers

Acyclovir and vidarabine in the treatment of ulcerative herpes simplex keratitis

Multicenter trial of acyclovir and trifluorothymidine in herpetic keratitis

Efficacy of (E)-5-(2-bromovinyl)-2'-deoxyuridine m the topical treatment of herpes simplex keratitis

Update on clinical trials with exogenous interferon

Combination therapy of dendritic keratitis with trifluorothymidine and interferon